BMS Selects ICON As Preferred Provider for Early Phase

ICON has been selected by Bristol-Myers Squibb as a preferred provider for full-service clinical pharmacology and exploratory clinical studies. ICON also provides global support for BMS’ clinical development pipeline, per the companies’ June 2010 agreement.

ICON will provide a broad range of early phase services from its Clinical Pharmacology Units in San Antonio, TX, Omaha, NE, and Manchester, UK, as well as scientific services such as protocol design and development, project management, clinical monitoring, medical monitoring/pharmacovigilence, data management, biostatistics, pharmacokinetics and medical writing.

“We are pleased that Bristol-Myers Squibb has again chosen ICON to bring greater operational efficiencies and high quality science to their drug development programs,” said Dr. Mario Rocci, president, ICON Development Solutions. “Both companies already have a very successful global partnership for phase II-IV clinical development and central laboratory services and we look forward to demonstrating the same value and efficiencies to BMS’ early phase clinical programs. Our global network of clinical research units, scientists and project teams, underpinned by world class technology, will drive significant cost savings and productivity.”